Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 53, Issue 12, 2012, Pages 2412-2418

  Tong, Hongyan ^a   Hu, Chao ^a   Zhuang, Zhengping ^b   Wang, Lijun ^a   Jin, Jie ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Hypoxia; Hypoxia inducible factor 1 ; Immunohistochemistry; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACLACINOMYCIN; CYTARABINE; HEMOGLOBIN; HOMOHARRINGTONINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RECOMBINANT COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE AGE; BONE MARROW; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOLOGICAL MARKERS; BONE MARROW; BONE MARROW CELLS; DISEASE PROGRESSION; FEMALE; HEMOGLOBINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84868339107     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.696637     Document Type: Article

References (34)

1. Garcia JS, Jain N, Godley LA. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Onco Targets Ther 2010;3:1-13.
2. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-1803.
3. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002;16:1151-1162. (Pubitemid 34815403)
4. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447-5454.
5. Abdel-Aleem S, St Louis JD, Hughes GC, et al. Metabolic changes in the normal and hypoxic neonatal myocardium. Ann NY Acad Sci 1999;874:254-261. (Pubitemid 29351946)
6. Semenza GL. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004;5:405-406. (Pubitemid 38610240)
7. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732. (Pubitemid 37328811)
8. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-2245.
9. d e Jonge HJ, Valk PJ, Veeger NJ, et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010;116:1747-1754.
10. Dorević G, Matusan-Ilijas K, Babarović E, et al. Hypoxia inducible factor-1 alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2009;28:40.
11. Shyu KG, Hsu FL, Wang MJ, et al. Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma cell invasion. Exp Cell Res 2007;313:1181-1191. (Pubitemid 46437248)
12. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008;8:790-797.
13. Xiao Z, Liu Q, Zhao B, et al. Hypoxia induces hemorrhagic transformation in pituitary adenomas via the HIF-1 signaling pathway. Oncol Rep 2011;26:1457-1464.
14. Brito LG, Schiavon VF, Andrade JM, et al. Expression of hypoxiainducible factor 1-and vascular endothelial growth factor-C in locally advanced breast cancer patients. Clinics (Sao Paulo) 2011;66: 1313-1320.
15. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxiainducible factor-1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-2916. (Pubitemid 32691934)
16. Birner P, Schindl M, Obermair A, et al. Expression of hypoxiainducible factor 1 alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-1668. (Pubitemid 32708633)
17. Liang X, Zheng M, Jiang J, et al. Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma. Oral Oncol 2011;47: 92-97.
18. Park S, Ha SY, Cho HY, et al. Prognostic implications of hypoxiainducible factor-1 in epidermal growth factor receptor-negative nonsmall cell lung cancer. Lung Cancer 2011;72:100-107.
19. Wellmann S, Guschmann M, Griethe W, et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004;18:926-933. (Pubitemid 38714616)
20. Ghosh AK, Shanafelt TD, Cimmino A, et al. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 2009;113:5568-5574.
21. Stewart M, Talks K, Leek R, et al. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology 2002;40:253-260. (Pubitemid 34227116)
22. Deeb G, Vaughan MM, Mclnnis I, et al. Hypoxia-inducible factor-1 protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res 2011;35:579-584.
23. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011;14:191-201.
24. Monti E, Gariboldi MB. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol 2011;4:62-77.
25. Sullivan R, Paré GC, Frederiksen LJ, et al. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 2008;7:1961-1973.
26. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
27. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088. (Pubitemid 27132124)
28. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5835.
29. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000;72: 131-133.
30. Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006;76:23-32.
31. Lin J, Yao DM, Qian J, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res 2008;32:1541-1545.
32. Zhang Y, Zhao D, Zhao H, et al. Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis. Med Oncol 2012 Jan 19. [Epub ahead of print]
33. Wu SJ, Yao M, Chou WC, et al. Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 2006;135: 317-323. (Pubitemid 44484838)
34. Benetatos L, Dasoula A, Syed N, et al. Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes. Leukemia 2008;22:1293-1295. (Pubitemid 351833811)